Branstrom A A, Midha S, Goldman R C
Advanced Medicine, Inc., 8 Clarke Drive, 08512, Cranbury, NJ, USA.
FEMS Microbiol Lett. 2000 Oct 15;191(2):187-90. doi: 10.1111/j.1574-6968.2000.tb09338.x.
An in situ transglycosylase assay has been developed using endogenously synthesized lipid II. The assay involves the preferential synthesis and accumulation of lipid II in a reaction mixture containing the cell wall membrane material isolated from Escherichia coli, exogenously supplied UDP-MurNAc-pentapeptide, and radiolabeled UDP-GlcNAc. In the presence of Triton X-100, the radiolabeled product formed is almost exclusively lipid II, while the subsequent formation of peptidoglycan is inhibited. Removal of the detergent resulted in the synthesis of peptidoglycan (25% incorporation of radiolabeled material) from the accumulated lipid II. This reaction was inhibited by moenomycin, a known transglycosylase inhibitor. In addition, tunicamycin, which affects an earlier step of the pathway by inhibiting MraY, had no effect on the formation of peptidoglycan in this assay, as expected. Similarly, ampicillin and bacitracin did not inhibit the formation of peptidoglycan under the conditions established.
已利用内源性合成的脂 II 开发了一种原位转糖基酶测定法。该测定法包括在含有从大肠杆菌分离的细胞壁膜材料、外源供应的 UDP-胞壁酰五肽和放射性标记的 UDP-葡萄糖胺的反应混合物中优先合成和积累脂 II。在 Triton X-100 存在下,形成的放射性标记产物几乎完全是脂 II,而随后肽聚糖的形成受到抑制。去除去污剂导致从积累的脂 II 合成肽聚糖(放射性标记物质的掺入率为 25%)。该反应被已知的转糖基酶抑制剂莫能菌素抑制。此外,如预期的那样,通过抑制 MraY 影响该途径早期步骤的衣霉素对该测定中肽聚糖的形成没有影响。同样,在既定条件下,氨苄青霉素和杆菌肽也不抑制肽聚糖的形成。